The conference room on the twenty-second floor of the plaintiffs' counsel's building had been stripped of everything but a long table, eight chairs, and a court reporter whose fingers hovered over her steno machine like a pianist waiting for the downbeat.
Claire took the oath with her right hand raised and her left flat on the table to keep it from shaking.
"Counsel, you may begin," the reporter said.
The plaintiffs' attorney, a wiry woman named Delgado with a gray bob and reading glasses pushed up into her hair, smiled at her like they were old friends. They were not.
"Ms. Bennett, in your own words, walk us through the adverse-event reporting structure at Helix as it existed when you joined."
Claire had rehearsed this answer forty times. She gave it anyway, clean and chronological, the org chart and the flag thresholds and the fact that cardiac events in women under forty-five had been folded into a catch-all category called *atypical presentations*—a phrase she had once written herself, in a slide, without thinking.
"Who created that category?"
"I don't know who created it. It predates me."
"Who maintained it?"
"My division. Under my predecessor."
"And when you became director?"
"I changed it. First week."
"Because?"
"Because four thousand eight hundred and twelve charts said it was killing people."
Delgado let that sit. The court reporter's keys clicked. Claire had learned that silence in a deposition wasn't a pause—it was a question, and if you were smart you didn't answer it.
Helix's counsel, a man named Ostrander with a soft voice and a corporate-litigation tan, leaned forward. "Objection, narrative. Ms. Bennett, you're not a physician. Correct?"
"No."
"You're not a statistician."
"No."
"Your background is product management."
"Yes."
"So when you say the category was *killing people*, that's your characterization, not a clinical finding."
"It's the characterization of a model my team retrained on corrected data, which flagged seventy-one percent of missed events in women under forty-five. That's a finding. You can call it whatever you want."
Ostrander's pen stopped. He hadn't expected the number to come out that fast.
They went at her for two hours. The routing slip. The memo. Whether she had known the identity of the anonymous sender before she disclosed it in the charter—yes, and she would not name them, and Ostrander could file a motion about it, and Delgado could argue privilege, and everyone in the room understood the fight would be about the *when*, not the *what*.
"Did you personally approve the initial trial protocols that excluded female-specific endpoints?"
Claire's mouth went dry. This was the one they'd been saving.
"I inherited them."
"Did you approve them?"
"For eight months. Yes."
"And in those eight months, how many women presented with symptoms the model discounted?"
"Objection," Delgado said.
"Withdrawn," Ostrander said, pleasantly, because he'd gotten what he wanted. The number was already in the record, and so was Claire's face when she said *eight months*.
They broke for water at the two-hour mark. Claire walked to the window and looked down at the harbor, whitecaps on gray water, a tugboat shouldering a barge toward the seaport. She'd grown up ten miles south of here and had never once imagined standing in this room under oath.
She turned, and there he was.
Ethan sat in the last row of the gallery, coat still on, hands folded. He'd come in sometime during hour one without her noticing. He didn't smile—he wasn't a smiler, not in rooms like this—but he nodded once, small and deliberate.
She nodded back and returned to the table.
The afternoon turned surgical. Ostrander produced an email she'd sent two years ago in which she'd written *the flag threshold may be over-tuned for the demo*—a sentence about a sales presentation that he now held up as proof she'd known the model was broken and shipped it anyway.
"Read the next line," Claire said.
"I beg your pardon?"
"Read the next line of the email. It says we should raise the threshold before the FDA submission and that I'd flagged it to my VP that morning. You have the whole document. Read it."
Ostrander's jaw tightened. He read it.
Delgado asked her three more questions after that, and then it was over.
She made it to the elevator before her hands started. Ethan caught up as the doors slid shut, and neither of them said anything until the car emptied at the lobby.
"You did good," he said.
"I said *eight months* in front of a stenographer."
"You said it accurately."
"It's in the record forever."
"It was already in the record. You just put your name on it." He pushed through the revolving door and held it for her, and the cold off the harbor hit them both. "That's the part that costs."
They walked two blocks without talking. Claire's phone had been buzzing since the lunch recess—Maria, Maria, Maria, then a number she didn't recognize, then Maria again. She stopped on the corner of Congress and State and read.
Maria: *they posted the peer review docket. Item four is the charter vote. Eleven days.*
Maria: *i called the board secretary three times about the secret meeting minutes. she says they don't exist.*
Maria: *what do you want me to do*
Claire typed with cold thumbs. *If the secretary says they don't exist, ask her for the retention schedule in writing. If she won't put it in writing, we subpoena her.*
Maria: *that's aggressive*
Claire: *that's the point*
She looked up. Ethan was watching her with an expression she was starting to recognize—the one he got when she did something he approved of and didn't want to admit it.
"Mount Auburn called again," he said.
Claire put the phone in her pocket. "When?"
"Tuesday."
"You didn't tell me."
"I'm telling you now."
The light changed. Neither of them moved. "What are you going to do?" she asked.
"I don't know yet." He looked at the traffic instead of her. "Before the journal piece, it was a job. Now it's a job where I'd be leaving a lawsuit and a patient advisory group and—" He stopped.
And me, Claire thought, and did not say.
"—and Rachel's name on a paper," Ethan finished. "It's harder to walk away from a thing you're in the middle of."
"You don't owe her the rest of your career."
"Maybe not." He met her eyes. "But I've got eleven days to figure out whether *I* want it, and that's a different question than whether I owe it."
She let that land. Somewhere behind them, a siren wound up and faded toward Government Center.
"Come to the group meeting Thursday," she said. "Maria's demanding the minutes formally. She wants you there."
"She wants me there, or you do?"
"Don't make me answer that on a street corner."
His mouth twitched—not quite a smile. "Thursday."
Her apartment was dark when she got home. She hung up her coat, sat on the kitchen floor with her back against the cabinets because the chair felt like too much commitment, and read the deposition notification that had come through while she walked: a supplement from Ostrander's office, filed with the court an hour ago.
Eight new exhibits. She scrolled.
Exhibit 14 was a routing slip.
She zoomed. The scan was grainy, three-hole-punched, the kind of carbon-copy internal form Helix had stopped using in 2019. Initials in the corner where the data-removal authorization had been signed off, passed from regulatory affairs to the CMO's office and back.
The initials were W.K.
Not the board member. Not the woman who had confirmed Claire's promotion.
Warren Kessler had signed the authorization to strip women's symptom data from the training set, and then spent six months demanding an external review of the woman who'd caught him.
Claire sat on the floor for a long time with the phone glowing in her hand. Then she called Maria.
"Don't say anything to the group yet," she said. "Thursday, we do this in order. Minutes first. Then the routing slip."
"Then what?"
"Then we find out whether the board will look at exhibit fourteen before they vote on item four."
She hung up. Her heart was going—hard, fast, and for once the number didn't scare her.